A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma

被引：0
|
作者：
Apolo, Andrea Borghese
Parnes, Howard L.
Madan, Ravi Amrit
Gulley, James L.
Wright, John Joseph
Khadar, Kattie
Trepel, Jane B.
Schlom, Jeffrey
Arlen, Philip M.
Merino, Maria
Steinberg, Seth M.
Choyke, Peter L.
Lindenberg, Maria Liza
Kurdziel, Karen A.
Folio, Les
Figg, William Douglas
Agarwal, Piyush K.
Bottaro, Donald P.
Dahut, William L.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Rockville, MD USA
[5] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[6] NCI, Lab Tumor Immunol & Biol, Med Oncol Branch, Bethesda, MD 20892 USA
[7] NCI, NIH, Bethesda, MD 20892 USA
[8] NCI, Biostat & Data Management Sect, CCR, Bethesda, MD 20892 USA
[9] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[10] NCI, Mol Imaging Program, CCR, NIH, Bethesda, MD 20892 USA
[11] NIH, Bethesda, MD 20892 USA
[12] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[13] NCI, Urol Oncol Branchd, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4589
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CABOZANTINIB (XL184) AT 40 MG IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): RESULTS OF A PHASE 2 NON-RANDOMIZED EXPANSION COHORT (NRE)
    de Bono, J. S.
    Smith, M. R.
    Rathkopf, D.
    Corn, P. G.
    Mukherji, D.
    Harzstark, A. L.
    Sartor, O. A.
    Smith, D. C.
    Tunariu, N.
    Sweeney, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 296 - 296
  • [42] Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    Apolo, Andrea B.
    Nadal, Rosa
    Girardi, Daniel M.
    Niglio, Scot A.
    Ley, Lisa
    Cordes, Lisa M.
    Steinberg, Seth M.
    Sierra Ortiz, Olena
    Cadena, Jacqueline
    Diaz, Carlos
    Mallek, Marissa
    Davarpanah, Nicole N.
    Costello, Rene
    Trepel, Jane B.
    Lee, Min-Jung
    Merino, Maria J.
    Bagheri, Mohammad Hadi
    Monk, Paul
    Figg, William D.
    Gulley, James L.
    Agarwal, Piyush K.
    Valera, Vladimir
    Chalfin, Heather J.
    Jones, Jennifer
    Streicher, Howard
    Wright, John J.
    Ning, Yangmin M.
    Parnes, Howard L.
    Dahut, William L.
    Bottaro, Donald P.
    Lara, Primo N., Jr.
    Saraiya, Biren
    Pal, Sumanta K.
    Stein, Mark N.
    Mortazavi, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3672 - +
  • [43] Cabozantinib (XL184) inhibits growth of prostate cancer in the bone and results in an altered bone environment
    Nguyen, Holly M.
    Brown, Lisha G.
    Gross, Ted S.
    Vessella, Robert L.
    Schimmiller, Frauke
    Corey, Eva
    CANCER RESEARCH, 2012, 72
  • [44] NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY
    Shih, Chie-Schin
    Blakely, Jaishri
    Clapp, Wade
    Wolters, Pam
    Dombi, Eva
    Cutter, Gary
    Ullrich, Nichole
    Allen, Jeffrey
    Packer, Roger
    Goldman, Stewart
    Gutmann, David
    Plotkin, Scott
    Rosser, Tena
    Robertson, Kent
    Widemann, Brigitte
    Korf, Bruce
    Fisher, Michael
    NEURO-ONCOLOGY, 2018, 20 : 142 - 142
  • [45] Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC)
    Choueiri, T. K.
    Pal, S. K.
    Cabanillas, M. E.
    Ramies, D. A.
    Tseng, L.
    Holland, J. S.
    Morrissey, S.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
    Yang, Pei-Wen
    Liu, Yu-Cheng
    Chang, Ya-Han
    Lin, Ching-Ching
    Huang, Pei-Ming
    Hua, Kuo-Tai
    Lee, Jang-Ming
    Hsieh, Min-Shu
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [47] A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer
    Choudhury, Atish D.
    Gray, Kathryn P.
    Supko, Jeffrey G.
    Harshman, Lauren C.
    Taplin, Mary-Ellen
    Pace, Amanda F.
    Farina, Matthew
    Zukotynski, Katherine A.
    Bernard, Brandon
    Kantoff, Philip W.
    Pomerantz, Mark
    Sweeney, Christopher
    PROSTATE, 2018, 78 (14): : 1053 - 1062
  • [48] Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: A phase II study
    Baitar, Abdelbari
    De Vos, Machteld
    Vandebroek, An
    Schrijvers, Dirk
    JOURNAL OF GERIATRIC ONCOLOGY, 2011, 2 (01) : 31 - 35
  • [49] Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma or renal cell carcinoma
    Maia, Manuel Caitano
    Agarwal, Neeraj
    McGregor, Bradley
    Vaishampayan, Ulka
    Choueiri, Toni K.
    Green, Marjorie
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Powles, Thomas
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [50] Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)
    DePrimo, S.
    Wu, B.
    Huang, S.
    Bautista, R.
    Cancilla, B.
    Vysotskaia, V.
    De Groot, J.
    Prados, M.
    Buller, R.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345